Pueraria lobata peptides ameliorate type 1 diabetes with involvement of the gut-pancreas axis: Insights from intestinal barrier, gut microbiota, and pancreatic protection.
Abstract
This study aimed to investigate the intervention effects of Pueraria lobata peptides (PLPs) on type 1 diabetes (T1D) and elucidate the underlying mechanisms from the perspective of the "gut-pancreas axis." In a streptozotocin (STZ)-induced T1D mouse model, an 8-week PLPs intervention (particularly at 400 mg/kg/day) significantly ameliorated hyperglycemia, restored glucose homeostasis, and maintained functional pancreatic β-cell mass. Mechanistic studies revealed that the multi-target protective effects of PLPs are closely associated with the systemic regulation of the gut-pancreas axis. PLPs exerted their benefits by enhancing intestinal barrier integrity (upregulating the expression of tight junction proteins, including Occludin, Claudin-1, and ZO-1, and reducing serum endotoxin levels), remodeling the gut microbiota structure (enriching beneficial genera such as Akkermansia), and consequently alleviating the inflammatory response from the colon to the pancreas (downregulating the expression of pro-inflammatory cytokines TNF-α and IL-1β while upregulating the anti-inflammatory cytokine IL-10). Furthermore, PLPs demonstrated inhibitory activity against carbohydrate-metabolizing enzymes and antioxidant capacity in vitro, providing fundamental support for their biological functions. These results indicate that PLPs may serve as a promising functional dietary ingredient targeting gut homeostasis.